MedPlus Health Services Limited has informed stock exchanges about a regulatory action affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a wholly-owned subsidiary, received a drug license suspension order from the Telangana Drugs Control Administration.

Suspension Details

The Assistant Director of Drugs Control Administration, Patancheru, Telangana, issued the suspension order for one of the subsidiary's stores. The affected outlet is situated at Kardanur Patancheru Shankarpalli Road in Telangana.

Regulatory Compliance

The suspension has been imposed under Rule 66(1) of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has made this disclosure in compliance with SEBI Regulation 30, which mandates listed entities to inform exchanges about material events and regulatory actions.

Financial Impact

MedPlus Health Services has quantified the potential financial impact of this regulatory action. The company estimates a potential revenue loss of Rs 0.20 lacs due to the one-day suspension of the store's operations.

Disclosure Requirements

The company has fulfilled its disclosure obligations pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The information has been made available on the company's website and will also be accessible on BSE and NSE websites for stakeholder reference.

MedPlus Health Services Limited has announced its quarterly earnings call to discuss the unaudited financial results for the quarter ended December 31, 2025. The announcement, made on January 22, 2026, follows the company's regulatory obligations under SEBI guidelines for listed entities.

Earnings Call Schedule

The company has scheduled the analyst and institutional investor meet for the Q3FY26 results discussion with specific timing and participation details.

Regulatory Compliance

The earnings call announcement has been made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to inform stock exchanges about material events and developments that could impact investor decisions.

Participation Options

MedPlus Health Services has provided comprehensive joining information to facilitate participation from analysts and institutional investors. The company offers two primary participation methods:

Pre-Registration Option

Participants can pre-register through a dedicated online link to join the call without waiting for operator assistance, streamlining the connection process.

Dial-In Access

Traditional dial-in numbers are available for participants who prefer telephone access. The company recommends joining 10 minutes prior to the scheduled time to ensure timely connection.

Information Availability

The earnings call details and joining information will be made available across multiple platforms to ensure broad accessibility. The company has confirmed that all relevant information will be accessible through its official website at www.medplusindia.com , as well as on the official websites of both stock exchanges - BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Limited ( www.nseindia.com ).

The announcement was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements. This structured approach to earnings communication demonstrates the company's commitment to transparent investor relations and regulatory adherence.